The analysis of the PRISM data also identified the interaction between the driver gene KMT2C and the drug Capecitabine, an oral prodrug of 5-fluorouracil that targets TYMS and is commonly used in the treatment of advanced gastric cancer 48,49. The gene discussed is KMT2C; the disease is gastric cancer.